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Selective effect of thiazides on the human osteoblast-like cell line
MG-63. Thiazide diuretics have been shown to decrease bone-loss rate
and to improve bone mineral density in patients using this medication.
However, the exact role of thiazides on bone cells is still debated. In the
present work, we studied whether thiazides could affect the normal
features of osteoblasts using the human model cell line MG-63. Hydro-
chlorothiazide (HCTZ) did not affect cell growth nor DNA synthesis in
these cells, yet slightly increased alkaline phosphatase activity in these cells
at pharmacologically relevant concentrations. Under similar conditions,
HCTZ dose-dependently inhibited 1,25(OH)2D3-induced osteocalcin se-
cretion by these cells (maximal effect, —40 to 50%, P < 0.005). However,
HCTZ did not inhibit the basal production of osteocalcin in MG-63 cells
(without 1,25(OH),D3 induction), which was very low to undectable. Two
different thiazide derivatives, chlorothiazide and cyclothiazide, and two
structurally related sulfonamides with selective inhibition of carbonic
anhydrase (Acetazol amide) or hyperglycemic effects (Diazoxide) were
also tested. Chlorothiazide (1000 rM) inhibited osteocalcin secretion
(—42 12.7%) at doses 10-fold higher than HCTZ (100 jsM) while
cyclothiazide was effective at doses of 1 /LM (—27 3.6%), and hence
100-fold lower than HCTZ, compatible with the relative natriuretic effect
in vivo of these compounds. Acetazolamide (10 jiM) poorly affected
osteocalcin secretion at doses 100-fold higher than those needed in vivo to
inhibit carbonic anhydrase. Likewise, Diazoxide (100 jLM) poorly affected
osteocaicin secretion at doses known to promote its biological effect.
Higher doses of acetazolan,ide and diazoxide induced cell death. Neither
Acetazolamide nor Diazoxide affected alkaline phosphatase, whereas
chlorothiazide had a weak positive effect on this enzymatic activity. The
production of macrophage colony-stimulating factor (M-CSF) was stimu-
lated in the presence of 1,25(OH)2D3 (50 nM), TNF-a (2 ng/ml) or both in
MG-63 cells. HCTZ (25 jiM, 24 hr of preincubation) did not modify basal
M-CSF production and did not reduce the response to 1,25(OH)2D3
alone. In contrast, HCTZ inhibited the response to TNF-a alone (P <
0.05), and also reduced the response to a combination of 1,25(OH)2D3
and TNF-cs (P < 0.01). In conclusion, these results indicate that thiazide
diuretics show a selective inhibion of osteocalcin secretion and M-CSF
production by MG-63 cells unlike structurally related drugs. Therefore,
these features may explain, in part, the positive effect of thiazides on bone
mineral density.
In renal cells, the action of thiazides was first believed to be
indirect. This was based on the lack of correlation between the
degree of tubular secretion of thiazides and their natriuretic effect
when infused in the renal portal system of the hen using the
Sperber technique [1]. Supporting this hypothesis of a peritubular
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rather than a luminal action of thiazides, Dan and Gemba [2]
reported that hydrochlorothiazide (HCTZ) significantly stimu-
lated ATP-dependent Ca24 uptake by microsomes. However,
HCTZ was only effective at a concentration of 0.5 m and the
authors failed to clearly demonstrate the exact nature of their
"microsomal" preparations.
In contrast, Costanzo and Windhager [3] and Costanzo [4]
showed, with a microperfusion technique in vivo, that chlorothi-
azide (CTZ) was acting from the lumen of the tubule. CTZ
increased net Ca2 and reduced net sodium (Na) reabsorption.
Therefore the mechanism of action of thiazides was still unclear.
In elegant binding experiments, Beaumont, Vaughn and Fanestil
[5] showed that [3H]-metolazone, a diuretic with a thiazide-like
mechanism of action, labels a site in rat kidney membranes that
has characteristics of the thiazide-sensitive ion transporter. The
binding of [3H]-metholazone was later found only in the luminal
membrane of distal tubules by the same group [6]. In vitro,
thiazides act directly on the luminal membrane of the distal tubule
to increase calcium uptake [7, 8], whereas luminal membrane of
the proximal tubules are insensitive to the treatment [8].
Recent data also suggest a positive role of thiazides on bone [9].
Wasnich et al [10, 11] reported an increase in bone mineral
density (by single photon absorptiometry) in patients treated with
thiazides alone or in combination with estrogens. The long-term
use of thiazides also results in a low prevalence of bone fractures
in aged patients [12, 131, art effect not observed by Adland-
Davenport et a! [14]. However, a small number of patients was
used in this study group (58 women) compared with the studies of
Wasnich et al (993 women [lfl, 1368 men [101) or those from
Cauley and Cumming (9707 women) [12] and could explain these
discrepancies. In contrast, a longitudinal study (5 years) of 325
men showed a decrease in bone-loss rate with thiazides [15]. In
this study, men using antihypertensive medications other than
thiazide showed an increase in bone-loss rate, providing more
evidence that thiazides reduce fracture risk by preserving bone
mass. LaCroix et al also concluded that, with a cohort of 9518 men
and women, the use of thiazide diuretics reduced the risk of hip
fracture by approximately one third [16]. Lemann et al [17] also
reported that hydrochlorothiazide reduced bone resorption in
healthy men despite elevated 1,25(OH)2D3 ]evels. Thus, these
studies point to a direct action of thiazides on bone metabolism.
Moreover, a recent meta-arialysis of a number of clinical studies
suggests that thiazides should be considered as part of an ap-
proach to osteoporotic fracture prevention, particularly in hyper-
tensive subjects [181.
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In the present study, we examined whether thiazides may have
a positive role on bone mineral density by acting on the prolifer-
ation of osteoblasts, the differentiation of osteoblasts or on the
release of mediators of bone resorption. We used the human
osteosarcoma cell model, MG-63, which reproduces some of the
features of osteoblast-like cells in l-'itro. With this model cell line
we observed that thiazides seem to act directly on parameters that
in vivo would regulate the activity of osteoclasts, which may
explain their positive role on bone mineral density.
Methods
Cell culture and DNA synthesis
Human osteosarcoma MG-63 cells were obtained through the
American Type Culture Collection (Rockville, MD, USA). They
were grown in HAMFI2/DMEM media containing 10% charcoal-
stripped fetal bovine serum (FBS) prepared as previously de-
scribed [193, 1% penicillin-streptomycin mixture (PS, Gibco) and
50 g/ml ascorbic acid. The cells were cultured in an incubator
gassed with 5% CO2 at 37°C. Culture medium was changed twice
a week. Cells were split once a week at a ratio of 1:9 with Trypsin
0.025%-EDTA 0.01% in phosphate buffered saline (PBS) pH 7.4
(Trypsin, EDTA). Confluent cells were treated with hydrochlo-
rothiazide (HCTZ, 0.01 to 100 MM) for 24 to 72 hours in a mixture
of HAMFI2/DMEM (1:1) containing 2% FBS and 50 jsg/ml
ascorbic acid. Where appropriate, the cells were incubated in
parallel with either 1,25(OH)2D3 (50 nM), TNF-a or their com-
bination. In another set of experiments, chiorothiazide (1000 /.LM),
cyclothiazide (1 jIM), acetazolamide (10 jIM) and Diazoxide (100jIM) were incubated in parallel to HCTZ for 48 hours in the
presence of 1,25(OH)2D3 (50 nM). MG-63 cells were then treated
as usual for the determination of alkaline phosphatase and
osteocalcin secretion.
The effect of hydrochlorothiazide on cellular growth was eval-
uated by the incorporation of 3H-thymidine in DNA following the
procedure described by Puzas and Brand [20]. Briefly, cells
treated with increasing doses of HCTZ or the vehicle for 48 hours
were incubated for the last three hours of culture in the presence
of 3H-thymidine. After three washings with PBS, cells were
solubilized and aliquots counted in a p-counter. Cells treated in
parallel with the vehicle or HCTZ at the same final concentrations
were used to evaluate total cell number. Cell death was also
evaluated by the trypan blue exclusion method. Cells treated with
HCTZ, chlorothiazide or acetazolamide as above were incubated
with 1% trypan blue for 30 minutes at 37°C in culture media. After
washing the cells twice with phosphate buffered saline, the cells
were split with Trypsin. EDTA as above, and cells were counted
with a haemocytometer. Results are given in terms of % cells not
taking the dye per total number of cells counted.
Alkaline phosphatase
Alkaline phosphatase (ALPase) activity was determined as the
release of p-nitrophenol hydrolyzed from p-nitrophenyl phos-
phate (12.5 mM) at 37°C for 30 minutes as previously described
[21—24]. Briefly, cells were first solubilized in ALPase buffer (100
mM glycine, 1 m'vi MgCI2, 1 mvi ZnC12, 1% Triton X-100, pH 10.5)
with agitation for 60 minutes at 5°C. All samples were then
sonicated for 5 seconds with an Ultrasonic Sonifier cell disruptor
at a setting of 5.
Osteocalcin determination
Confluent cells in 35 mm petri dishes were washed twice with
Hank's buffered salt solution (HBSS) containing: CaCl2, 1.26 mM;
KCI, 5.37 mvi; KH2PO4, 0.44 mM; MgCI2, 0.49 mM; MgSO4, 0.41
mM; NaCI, 136.9 mM; NaHCO3, 25 mM; Na2HPO4, 0.336 mM;
D-glucose, 5.55 msi, pH 7.4. The cells were then covered with 1 ml
of HAMF12/DMEM media containing 2% charcoal-stripped
FBS, 1% PS, 50 jIg/ml ascorbic acid and 108 menadione vitamin
K (Sigma, St. Louis, MO, USA), with or without 1,25(OH)2D3
and increasing doses of HCTZ (1 to 100 jIM). The media was
removed at the end of the incubation and frozen at —80°C. Cells
were washed again twice with HBSS, and either used to evaluate
final cell density, alkaline phosphatase (see above), or protein
determination by the method of Lowry et a! [211.
Osteocalcin determinations were done by RIA (Biomedical
Technologies Inc., Stoughton, MA, USA) with antibodies raised
against bovine osteocalcin that cross-react with human osteocal-
ci Osteocalcin was also determined on aliquots of the media
used for the incubations to correct for bovine osteocalcin contam-
ination, which was very low with the procedure used (< 0.1 nglml
with the final dilution) [19, 22].
Measurement of macrophage colony-stimulating factor
Confluent cells, plated on 35 mm petri dishes, were washed
twice with HBSS pH 7.4 and covered with I ml of HAMF12/
DMEM (1:1) media containing 2% FBS, 50 jIg/mi ascorbic acid
and 2 ng/mi TNF-a, 50 nrvt i,25(OH)2D2 or their combination, in
the presence or absence of hydrochlorothiazide (25 jIM). After 48
hours of incubation at 37°C, the supernatant was recuperated and
aliquots were taken to measure M-CSF by an in-house ELISA.
Briefly, 96 wells plates were coated with 10 jIg/mi of a goat
anti-human M-CSF antibody (R & D Systems, Minneapolis, MN,
USA) for two hours at 37°C. This was followed by the coating of
non-specific sites by a treatment with 5% gelatin in a carbonate
buffer pH 9.5 for two hours at 37°C. A standard curve was then
established with known amounts of recombinant human M-CSF
(Genzyme, Markham, Ontario, Canada) by incubating the cyto-
kine for one hour at 37°C. Cell culture media from both cell
cultures, at the appropriate dilution, were also incubated in
parallel with the standard curve. After washing the plates, a
polyclonal rabbit anti-human M-CSF (Genzyme) was added for
one hour at 37°C. The detection of this second antibody was
performed by the addition of a goat anti-rabbit antibody coupled
to a peroxydase (Organon Technika, Scarborough, Ontario,
USA). The detection of the peroxydase was evaluated by the
hydrolysis of 0.05% ABTS substrate (Organon Technika) for 30
minutes at 25°C in the presence of 0.1% H2O2. Plates were then
read on a plate reader at 405 flM and values determined against
the standard curve established in parallel. The validation of the
ELISA shows intra-assay variations of 6% and inter-assay varia-
tions of 8%.
Statistics
Statistical differences were evaluated by analysis of variance in
dose-response experiments and by two-tailed Student's t-tests. In
each case, the statistical test used is indicated and the number of
experiments is stated individually in the legend of each Figure.
Further analysis of dose-response experiments were performed by
the multiple comparison analysis of Bonferroni/Dunn with a
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Fig. 1. Effect of hydrochiorothiazide on DNA synthesis by MG-63 cells.
Cells were pretreated for 48 hours with increasing doses of HCTZ in
culture media containing 2% FBS. 3H-thymidine was added for the last
three hours of incubation, and incorporation into DNA was evaluated on
aliquots after the soluhilization of cells in 1 N NaOH overnight at 4°C. The
results are the mean SEM of 7 experiments with triplicate dishes per
condition. < 0.025.
computer assisted program (StatView 4.0 from MacIntosh). A
level of 5% for the Bonferroni/Dunn analysis was chosen as
significant.
Results
Cellular proliferation
Cellular proliferation was evaluated by the incorporation of
3H-thymidine in MG-63 cells in response to increasing doses of
hydrochiorothiazide (Fig. 1). The diuretic (up to 300 jIM) failed to
modify DNA synthesis by MG-63 cells. Higher concentrations
(500 jIM) of HCTZ produced slight reductions in DNA synthesis,
that could be due to a toxic effect of this diuretic at these high
doses. Indeed, cellular death was evaluated in response to the
different thiazide diuretics used and to acetazolamide by the
trypan blue exclusion method. Figure 2 shows that HCTZ (100
jIM) and ehlorothiazide (1000 jIM) did not induce significant cell
death at these maximal concentrations as compared to controls,
whereas acetazolamide induced cell death at doses higher than 10
jIM as compared to controls, HCTZ and chlorothiazide.
Alkaline phosphatase activity
In contrast to the absence of an effect on DNA synthesis, HCTZ
slightly but dose-dependently stimulated i,25(OH)2D3-induced
alkaline phosphatasc activity in MG-63 cells (Fig. 3). The increase
in alkaline phosphatase activity was gradual, and a significant
effect of the diuretic was noted at doses as low as 1 jIM (P < 0.005
by analysis of variance, Fig. 3). The Bonferroni/Dunn multiple
analysis further indicated a significant difference (P < 0.05)
Fig. 2. Effect of HCTZ, chlorothiazide (Chloro) and acetazolamide (Aceta)
on cell growth by MG-63 cells. Cells were incubated for 48 hours with 100
jIM HCTZ, 1000 jIM Chloro, 1 jIM Aceta or the vehicle (CTL) in culture
media containing 2% FBS. At the end of this incubation, cells were stained
with 1% trypan blue for 30 minutes at 37°C, split by Trypsin. EDTA
treatment and counted. Values represent the relative percentage of viable
cells over total viable cells counted in controls. Results are expressed as
mean SOM of four separate experiments with three dishes per conditions
tested. *J) < 0.005 versus CTL and HCTZ, **,D < 0.05 versus Chloro.
between 0 (control) and I or 10 LM HCTZ, and between 0.1 fLM
and 10 jIM, hence indicating that the effect saturated between ito
100 jIM. Higher doses (up to 500 jIM) caused a further increase in
alkaline phosphatase activity while reducing DNA synthesis, but
this was associated with a toxic effect of the diuretic as assessed by
the trypan blue exclusion method (not shown).
Osteocalcin secretion
In contrast to the increase in alkaline phosphatase activity
induced by HCTZ in MG-63 cells, osteocalcin secretion was
strongly reduced by this diuretic (Fig. 4). Our results indicated
that osteocalcin release in the absence of 1,25(OH)2D3, which is
very low in MG-63 cells, was not affected by HCTZ. However,
HCTZ dose-dependently (1 to 100 /LM) inhibited 1,25(OH)7D3-
induced osteocalcin secretion by these cells (Fig. 4, P < 0.005 by
analysis of variance). The Bonfcrroni/Dunn multiple comparison
analysis further indicated significant differences between 0 (con-
trol) and 10 and 100 /.tM HCTZ, and between 1 and 100 jIM HCTZ
(P < 0.05 for all comparisons). This inhibition ranged between 30
to 50% in the presence of 10 to 100 jIM HCTZ.
Production of macrophage colony-stimulating factor
Using an in-house ELISA for the measure of M-CSF (range,
0.05 to 5 U/mI; recovery, 89.7 4.4%), we evaluated that MG-63
cells can release constitutively M-CSF at a rate of 1.5 U/mg
protein/48 hours. This basal release of M-CSF is stimulated in
MG-63 cells about twofold by 1,25(OH)2D1 (P < 0.05), TNF-a
(P < 0.005) or a combination of both agents (P < 0.005). The
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Fig. 3. Dose-dependent effect of hydrochlorothiazide on alkaline phos- Fig. 5. Effect of hydrochiorothiazide on macrophage colony-stimulating
phatase activity. Cells were treated as described in Figure 1 with the factor release by MG-63 cells. Cells were incubated for 48 hours in the
addition of 1,25(OH)2D1 (50 nM) for the last 48 hours of culture. They
were then solubilized in ALPase buffer and enzymatic activity determined
presence or absence of 1,25(OH)2D3 (50 nM) alone, TNF-a (2 nglml)
alone or their combination with (•) orwithout () HCTZ (25 /LM). At the
on aliquots. The results are the mean SCM of 6 preparations. P < 0.005 end of the incubation, aliquots of the supernatant were recuperated and
by analysis of variance. M-CSF evaluated by ELISA as described in the Methods section. The
results are the mean SEM of 4 to 6 experiments. P < 0.01, **p < 0.05
versus same treatment without thiazides. P < 0.001 for 1,25(OH)2D3,
140 TNF-a and 1,25(OH)2D1 + TNF-a versus CTL.
120 process (similar results were obtained for IL-la, not shown). In
contrast, the addition of HCTZ to a combination of l,25(OH)2D3
+ TNF-a produced a significant inhibition of their combined
effect on M-CSF release (50% inhibition, P < 0.01, Fig. 5).
Specificity of the thiazide effect of osteocalcin secretion
We next tested whether the inhibition of osteocalcin secretion
by MG-63 cells was a thiazide-like selective effect or if this was
related to their weak carbonic anhydrase inhibitory activity. As
40 shown in Figure 6, chlorothiazide (1000 .tM) reproduced the
inhibitory effect of HCTZ (100 jIM) on osteocalcin secretion
(—42 12.7%), albeit at a concentration 10 times that for HCTZ,
20 while cyclothiazide induced a similar inhibition (—27 3.6%) at
a concentration of 1 jIM. In contrast, the sulfonamide related
0 agent acetazolamide, which is a selective carbonic anhydrase
inhibitor, had no effect on this activity. Likewise, Diazoxide, a
HCTZ l.tM
structurally related sulfonamide derivative very similar to thia-
zides, also showed very poor inhibition of osteocalcin secretion
Fig. 4. Dose-dependent effect of hydrochiorothiazide on osteocalcin release
by MG-63 cells. Cells were treated as in Figure 1, with the addition of
1,25(OH)2D3 (50 nM). At the end of the incubation, aliquots of the
supernatant were used to determined osteocalcin by RIA. The results are
(Fig. 6). In comparison, PGE2, which is one of the most potent
inhibitor of osteocalcin secretion reduced this activity by 69.5
3 30/ F 6.. C 1.
the mean SEM of 4 experiments. P < 0.005 by analysis of variance. .Discussion
The exact mechanism of action for the positive effect of thiazide
treatment of MG-63 cells in parallel with hydrochlorothiazide did diuretics on bone mineral density in patients using this type of
not significantly inhibit the stimulating effect of 1,25(OH)2D1, yet medication instead of other diuretics or antihypertensive agents
reduced the stimulating effect of TNF-a (—40%, P < 0.05) on this has never been elucidated. Both a direct stimulating effect on
0 1 10 100
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Fig. 6. Specificity of thiazide derivatives on osteocalcin secretion. Confluent
cells were preincubated for 48 hours with either HCTZ (100 jLM),
chiorothiazide (Chloro, 1000 jrM), cyclothiazide (Cyclo, 1 rM), Acetazol-
amide (Aeeta, 1 j.LM) or Diazoxide (Diazo, 100 /LM) in culture media
containing 2% FBS and 50 flM 1,25(OH)2D1. At the end of the incubation,
osteocalcin release was determined on aliquots of cell culture media by
RIA. The results are the mean SCM of 5 to 12 experiments run in
triplicate. *p < 0.001, < 0.005 versus Control.
bone formation rate/osteoblast growth or an inhibiting effect on
bone resorption (or both) could potentially explain this important
clinical finding. Moreover, this effect may potentially directly
affect the cells responsible for these mechanisms or yet may be
indirect via the regulation of other effectors. The present study
indicates that osteoblasts are targets for the action of thiazides,
and that this action is specific for thiazide derivatives.
Indeed, using the human osteoblast-like cell line MG-63, we
were able to demonstrate that hydrochiorothiazide, a diuretic
often prescribed to hypertensive patients, influences different
pathways in these cells. The diuretic was without effect on DNA
synthesis and cell growth by these cells in vitro, however, whether
this is also the case in vivo remains to be investigated. Hall and
Schaueblin obtained similar results with rat osteosarcoma UMR
cells [23], whereas Song and Wergedal presented data showing
that at I iM HCTZ, 3H-thymidine incorporation was increased in
human primary osteoblasts [241. This discrepancy between the
results of Song and Wergedal and ours may be related to the
length of exposition of cells to HCTZ (only two days in our
experimental protocol as opposed to seven days in theirs) or to the
use of primary human osteoblasts in the former study. The slight
increase in alkaline phosphatase activity measured in MG-63 cells
in vitro in response to HCTZ may reflect an increased differenti-
ation of these cells with thiazides, as these were the only drugs
tested that reproduced that effect, and because alkaline phos-
phatase is a good indicator of osteoblast-like cell differentiation.
However, serum alkaline phosphatase levels do not seem to be
influenced by thiazides in vivo [25-271, although none of these
studies were performed on large numbers of patients, and one
lasted only for a few days [27], inconsistent with the long-term
action of thiazides on bone metabolic parameters in vivo [9—131.
In addition, HCTZ influenced pathways involved in the trigger-
ing/recruitment of osteoclasts. The diuretic inhibited the release
of osteocalcin, a protein proposed to influence bone resorption
[28]. This inhibitory effect was observed in a range of concentra-
tion for HCTZ that is compatible with the doses obtained in
patients using this medication [29]. Hence, this in vitro inhibition
of osteocalcin release may also be present in these patients in vivo,
which may retard bone resorption. The direct inhibitory effect of
HCTZ on the release of M-CSF also indicates that this diuretic
can retard resorption. Indeed, the local release of M-CSF by
osteoblasts in vivo participates in the induction of bone resorption
either by the recruitment of preosteoclasts or by directly promot-
ing the differentiation of osteoclasts [30]. It is noteworthy that
HCTZ was more effective in the presence of TNF-a than in the
presence of 1,25(OH)2D3, since TNF-a is a more potent inducer
of bone resorption. Hence, thiazides could be more effective in
regulating the inhibitory action of TNF-a on bone mineral
density.
The effect of hydrochlorothiazide is specific to this class of
diuretics and does not result from secondary effects of these drugs
for several reasons. Chlorothiazide reproduced the effects of
HCTZ on both alkaline phosphatase activity and osteocalcin
secretion, albeit at doses 10-fold higher, compatible with their in
vivo natriuretic effects [31]. Cyclothiazide, a more potent thiazide
diuretic than HCTZ, also inhibited osteocalcin release at doses
100-fold lower than HCTZ compatible with its in vivo effect. This
inhibitory effect is probably not related to their carbonic anhy-
drase inhibitory capacities since HCTZ (100 rM) inhibited osteo-
calcin secretion as efficiently as chlorothiazide (1000 !LM), hence at
10-fold lower doses, whereas chlorothiazide is a much more
potent inhibitor of CA than HCTZ (15-fold) [31]. Moreover,
acetazolamide, a selective CA inhibitor, was unable to reproduce
the effect of HCTZ even at doses in the .rM range while in vivo its
maximal effect is observed at io M [32]. Only at 100 LM did it
slightly reduce osteocalcin secretion, a dose that also induced
cellular damage and death. Thiazides may also show phosphodi-
esterase inhibition, a situation that can reduce osteocalcin secre-
tion in MG-63 cells due to an elevation of intracellular cAMP [22].
However, the three thiazide diuretics used all inhibited osteocal-
cm secretion to similar levels whereas chlorothiazide should be
the most potent phosphodiesterase inhibitor, about 10- to 20-fold
as compared to HCTZ and cyclothiazide [33]. Finally, a structur-
ally related sulfonamide drug, Diazoxide, with known inhibitory
effects on insulin secretion [34], was unable to reproduce the full
effects of thiazides at effective doses. Indeed, its effect was
inconsistent and much weaker than with thiazides or POE2. In
contrast, PGE2, used at maximal effective doses, was shown to be
the most potent inhibitor of osteocalcin secretion under our
experimental setting, a situation directly related to its stimulation
of cAMP synthesis in MG-63 cells [22]. This result with POE2 also
indicates that osteocalcin secretion could not be inhibited by more
than 70% under the present experimental conditions, hence
suggesting that the inhibition observed in the presence of thiazide
derivatives (30 to 50%) is very potent as well.
in a rat model mimicking, in many ways, the events of human
urinary stone disease [35], McKee, Nanci and Khan [36] have
Control Aceta Diazo HCTZ Cyclo Chioro PGE2
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shown an intense immunolabeling for two "bone" proteins, osteo-
calcin and osteopontin. Osteocalcin is strictly produced by osteo-
blasts [19, 22, 281, whereas osteopontin is synthesized by renal
cells as well [37]. Since osteopontin and osteocalcin can form
supramolecular complexes in vitro [38], the combination of both
proteins may contribute to the organic backbone of kidney stones
as observed by McKee et a! in vivo [36]. Hence, the observation
that in vitro, thiazides inhibited osteocalcin release by osteoblast-
like cells suggest that this could participate in the reduction of
stone formation, but also in the reduction of bone resorption. It is
noteworthy that alendronate, a bisphosphonate used to reduce
bone resorption, reduces stone formation during immobilization
or bedrest [39], whereas this type of drug also reduces osteocalcin
release by osteoblasts in vitro [40]. Moreover, long-term use of
thiazides reduces serum parathyroid hormone and osteocalcin
levels in both aged men and women [411, and postmenopausal
women [421. Hence, since osteocalcin is only synthesized by
osteoblasts [28], these results also strongly suggest that thiazides
reduce osteocalcin synthesis and/or release in vivo, a situation that
we were able to show in vitro with a human osteoblast-like cell
model (MG-63 cells) using three types of thiazide diuretics. It also
indicates that this observed reduction in osteocalcin secretion by
MG-63 cells in response to thiazides is not due to culture
conditions nor to the cell type used.
Peripheral blood monocytes (PBMC) from calcium stone form-
ers with idiopathic hypercalciuria release large amounts of IL-13
and GM-CSF [43], and IL-1f3 can stimulate the release of M-CSF
and IL-6 by osteoblasts. M-CSF and IL-6 are potent inducers of
bone resorption, the first one through recruitment of precursor
cells for osteoclasts and/or stimulation of the differentiation of
these cells, whereas IL-6 would only enhance the second pathway.
The reduction of M-CSF production by osteoblast-like MG-63
cells with HCTZ in vitro would then suggest that in vivo thiazides
may also contribute to the reduction of bone resorption via this
pathway. In addition, Hall and Schaueblin reported that HCTZ, at
doses of 30 to 100 j.LM, directly inhibits bone resorption by isolated
neonatal rat osteoclasts in vitro [23]. Hence our results and theirs
suggest that thiazides may affect bone resorption via two path-
ways: directly on osteoclasts, and indirectly via the release from
osteoblasts of cytokines/proteins triggering osteoclasts.
In conclusion, thiazide derivatives like hydrochlorothiazide act
directly on osteoblast-like cells to inhibit the release of bone
resorbing factors, namely osteocalcin and M-CSF, while not
affecting the proliferation of osteoblast-like cells. This effect is
specific to thiazide-like structures, as related compounds did not
reproduce these effects.
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